Payment overview · 2025
General Payments
$392.61
16 reported records · 8 companies
Healthcare provider profile · identity verified
Anetha Moorthal, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · ZEPHYRHILLS, FL · NPI 1720207285
Verified facts
What the public records show
CMS Open Payments records show Anetha Moorthal, M.D received $392.61 in general payments during 2025 across 16 reported records.
Corcept Therapeutics accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $113.03 | 28.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.90 | 16.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.21 | 16.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.18 | 10.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.04 | 9.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.27 | 9.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.04 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.94 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $392.61 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $113.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.30 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.30 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 510 | 144 |
| Gabapentin | Gabapentin | 389 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 114 |
| Losartan Potassium | Losartan Potassium | 305 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 94 |
| Omeprazole | Omeprazole | 280 | 96 |
| Lisinopril | Lisinopril | 276 | 84 |
| Meloxicam | Meloxicam | 250 | 74 |
| Furosemide | Furosemide | 236 | 71 |
| Potassium Chloride | Potassium Chloride | 213 | 69 |
| Simvastatin | Simvastatin | 191 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 52 |
| Glipizide Er | Glipizide | 166 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 48 |
| Tramadol Hcl | Tramadol Hcl | 163 | 47 |
| Montelukast Sodium | Montelukast Sodium | 161 | 51 |
| Trazodone Hcl | Trazodone Hcl | 155 | 44 |
| Metformin Hcl | Metformin Hcl | 147 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 49 |
| Famotidine | Famotidine | 141 | 50 |
| Carvedilol | Carvedilol | 124 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 35 |
| Alprazolam | Alprazolam | 104 | 28 |
| Buspirone Hcl | Buspirone Hcl | 104 | 37 |
| Eliquis | Apixaban | 102 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 30 |
| Prednisone | Prednisone | 98 | 60 |
| Alendronate Sodium | Alendronate Sodium | 97 | 34 |
| Ezetimibe | Ezetimibe | 97 | 32 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 92 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 27 |
| Allopurinol | Allopurinol | 81 | 24 |
| Cephalexin | Cephalexin | 79 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 23 |
| Sertraline Hcl | Sertraline Hcl | 78 | 23 |
| Pregabalin | Pregabalin | 75 | 16 |
| Finasteride | Finasteride | 74 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | 13 |
| Glipizide | Glipizide | 66 | 19 |
| Temazepam | Temazepam | 66 | suppressed |
| Baclofen | Baclofen | 65 | 26 |
| Glimepiride | Glimepiride | 65 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 16 |
| Ozempic | Semaglutide | 59 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 15 |
| Nifedipine Er | Nifedipine | 58 | 15 |
| Atenolol | Atenolol | 55 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Celecoxib | Celecoxib | 48 | 14 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 16 |
| Mirtazapine | Mirtazapine | 44 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 32 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Cefdinir | Cefdinir | 36 | 32 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 22 |
| Warfarin Sodium | Warfarin Sodium | 30 | 11 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Linzess | Linaclotide | 28 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Novolin R | Insulin Regular, Human | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Droplet Insulin Syringe | Syrge-Ndl,ins 0.5 Ml Half Mark | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $392.61 · 16 records | Corcept Therapeutics | ABRYSVO, AREXVY, COMIRNATY, EVENITY, JARDIANCE, Korlym, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error